Home  »  Business   »  Is a Correction Looming Ahead for PTC Therapeutics...

Is a Correction Looming Ahead for PTC Therapeutics Inc. (PTCT)

PTC Therapeutics Inc. (NASDAQ:PTCT) went up by 2.95% from its latest closing price compared to the recent 1-year high of $48.88. The company’s stock price has collected 10.90% of gains in the last five trading sessions.

Is It Worth Investing in PTC Therapeutics Inc. (NASDAQ :PTCT) Right Now?

Plus, the 36-month beta value for PTCT is at 0.65. Opinions of the stock are interesting as 4 analysts out of 11 who provided ratings for PTC Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $49.90, which is -$0.79 below the current price. PTCT currently public float of 69.17M and currently shorts hold a 8.15% ratio of that float. Today, the average trading volume of PTCT was 787.21K shares.

PTCT’s Market Performance

PTCT stocks went up by 10.90% for the week, with a monthly jump of 14.73% and a quarterly performance of 34.11%, while its annual performance rate touched 27.94%. The volatility ratio for the week stands at 5.69% while the volatility levels for the past 30 days are set at 4.30% for PTC Therapeutics Inc. The simple moving average for the period of the last 20 days is 10.98% for PTCT stocks with a simple moving average of 29.20% for the last 200 days.

Analysts’ Opinion of PTCT

Many brokerage firms have already submitted their reports for PTCT stocks, with Cantor Fitzgerald repeating the rating for PTCT by listing it as a “Overweight.” The predicted price for PTCT in the upcoming period, according to Cantor Fitzgerald is $63 based on the research report published on April 04th of the current year 2022.

BofA Securities, on the other hand, stated in their research note that they expect to see PTCT reach a price target of $38. The rating they have provided for PTCT stocks is “Underperform” according to the report published on October 18th, 2021.

Credit Suisse gave a rating of “Neutral” to PTCT, setting the target price at $54 in the report published on April 26th of the previous year.

PTCT Trading at 31.90% from the 50-Day Moving Average

After a stumble in the market that brought PTCT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.72% of gains for the given period.

Volatility was left at 4.30%, however, over the last 30 days, the volatility rate increased by 5.69%, as shares surge +11.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.89% upper at present.

During the last 5 trading sessions, PTCT rose by +10.90%, which changed the moving average for the period of 200-days by +31.74% in comparison to the 20-day moving average, which settled at $44.62. In addition, PTC Therapeutics Inc. saw 23.60% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PTCT starting from Svoronos Dawn, who sale 738 shares at the price of $27.20 back on Jun 09. After this action, Svoronos Dawn now owns 29,017 shares of PTC Therapeutics Inc., valued at $20,074 using the latest closing price.

Peltz Stuart Walter, the CHIEF EXECUTIVE OFFICER of PTC Therapeutics Inc., sale 407 shares at $26.83 during a trade that took place back on Jun 07, which means that Peltz Stuart Walter is holding 38,239 shares at $10,919 based on the most recent closing price.

Stock Fundamentals for PTCT

Current profitability levels for the company are sitting at:

  • -69.62 for the present operating margin
  • +83.83 for the gross margin

The net margin for PTC Therapeutics Inc. stands at -97.27. Equity return is now at value -983.20, with -26.80 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.87.

A Lesson to Learn: Bumble Inc. (BMBL)

Bumble Inc. (NASDAQ:BMBL) went down by -1.68% from its latest closing price compared to the recent 1-year high of $61.05. The company’s stock price has